Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: A cost-effectiveness analysis using a transmission model
Author summary Why was this study done? Radical cure with primaquine or recently approved tafenoquine is required to clear the dormant liver parasites of vivax malaria. While single-dose tafenoquine overcomes the barrier of patient adherence to the current 7-day primaquine treatment, it costs more and requires screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency. While the impact of changing policies to tafenoquine after G6PD screening on transmission has been evaluated, the associated costs and cost-effectiveness will be important considerations for policymakers. What did th...
Source: plos.org